You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial

Article info

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial

Authors

  • Juliane Schuhmacher Department of Immunology, Institute for Cell Biology, University of Tübingen, Tubingen, Germany Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Sonja Heidu Department of Immunology, Institute for Cell Biology, University of Tübingen, Tubingen, Germany Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Torben Balchen Zelo Phase I Unit, DanTrials ApS, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • Jennifer Rebecca Richardson Department of Immunology, Institute for Cell Biology, University of Tübingen, Tubingen, Germany Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Camilla Schmeltz Zelo Phase I Unit, DanTrials ApS, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • Jesper Sonne Zelo Phase I Unit, DanTrials ApS, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • Jonas Schweiker Department of Oncology, Haematology, Immunology, Rheumatology and Pulmonology, University Hospital of Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Hans-Georg Rammensee Department of Immunology, Institute for Cell Biology, University of Tübingen, Tubingen, Germany Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), partner site Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Per Thor Straten Department of Oncology, Center for Cancer Immune Therapy (CCIT), University Hospital Herlev & Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • Martin Andreas Røder Department of Urology, Copenhagen Prostate Cancer Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • Klaus Brasso Department of Urology, Copenhagen Prostate Cancer Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • Cécile Gouttefangeas Department of Immunology, Institute for Cell Biology, University of Tübingen, Tubingen, Germany Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), partner site Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles

Citation

Schuhmacher J, Heidu S, Balchen T, et al
Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial
Journal for ImmunoTherapy of Cancer 2020;8:e001157. doi: 10.1136/jitc-2020-001157
Online issue publication 
November 12, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.